Scholar Rock Holding Corporation

NASDAQ:SRRK

Biotechnology

Healthcare
$48.00 +1.03%

+$0.49 today

Market cap
$5.86B
Beta
0.69
P/E (TTM)
-14.8
EPS (TTM)
-$3.21
52W Low $27.07High $52.19

Volume 2.77M

Average 1.46M

SRRK Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Scholar Rock Holding CorporationNASDAQ: SRRK

Accumulated OCI · Q3 FY2026 · quarter ended Sep 2026

Accumulated OCI rises 1287.2% from a year ago

Accumulated OCI stood at $1.62M at the end of Q3 FY2026, up 1287.2% from a year earlier and up 42.2% from the prior quarter.

Context

  • Accumulated OCI amounted to 0.4% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +1287.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.62M+42.2% QoQ
Last fiscal yearDec 2025
$94K-41.3% YoY
Year agoSep 2025
$117K+1287.2% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1287.2%——
1 year-41.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
94K USD
Year-over-year change
-41.3%

Accumulated OCI vs competitors

How SRRK compares with its peers on the latest reported figures

  • SRRK's Sep 2026 Accumulated OCI of $1.62M is the 2nd highest of the 11 companies compared; the peer median is -$244K.
  • Its year-over-year change of +1287.2% is the highest of 10, against a peer median of -455.9%.
  • Accumulated OCI amounts to 0.4% of total assets for SRRK, versus a peer median of 0.1%.
SRRK Competitors Peer median
Accumulated OCI for SRRK and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PTCTPTC Therapeutics, Inc.Jun 2026$6.02M -18.2%+29.9%0.2%
SRRKScholar Rock Holding CorporationSep 2026$1.62M +1287.2%—0.4%
BBIOBridgeBio Pharma, Inc.Jun 2026-$7K -800.0%—0.0%
STOKStoke Therapeutics, Inc.Mar 2026-$115K -10.6%—0.0%
SRPTSarepta Therapeutics, Inc.Mar 2026-$121K -455.9%—0.0%
MAZEMaze Therapeutics, Inc.Mar 2026-$135K ——0.0%
DYNDyne Therapeutics, Inc.Jun 2026-$353K -240.1%—0.0%
BEAMBeam Therapeutics Inc.Jun 2026-$2.19M -21990.0%—0.2%
XENEXenon Pharmaceuticals Inc.Sep 2026-$5.05M -1159.3%—0.4%
EWTXEdgewise Therapeutics, Inc.Sep 2026-$5.6M -899.1%—0.3%
IONSIonis Pharmaceuticals, Inc.Sep 2026-$39.82M -53.3%—1.4%
Peer median (excluding SRRK) -$244K-455.9%+29.9%0.1%

Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents212.84M103.28M101.86M177.88M323.53M
Short-term Investments40.16M212.09M178.08M259.4M44.04M
Net Receivables02.74M1.08M2.15M0
Inventory00000
Other Current Assets12.33M00017.58M
Total Current Assets265.32M328.02M288.19M451.17M385.15M
Property, Plant & Equipment (Net)35.01M25.93M16.02M18.41M12.09M
Goodwill00000
Intangible Assets004.07M2.4M0
Long-term Investments2.5M0000
Tax Assets00000
Other Non-current Assets1.62M4.22M2.75M2.96M7.04M
Total Non-current Assets39.13M30.14M22.84M23.76M19.13M
Total Assets304.45M358.17M311.04M474.92M404.27M
Account Payables4.43M3.99M3.47M10.1M10.3M
Short-term Debt8.98M01.33M05.55M
Tax Payables00000
Deferred Revenue33.19M0000
Other Current Liabilities3.13M222K85K019.45M
Total Current Liabilities64.3M36.39M32.74M46.94M55.42M
Long-term Debt48.42M49.74M48.68M50.15M99.71M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities68.07M61.54M53.08M59.35M103.37M
Total Liabilities132.37M97.93M85.82M106.29M158.78M
Common Stock35K52K76K94K108K
Retained Earnings(376.13M)(510.63M)(676.42M)(922.72M)(1.3B)
Accumulated OCI(35K)(884K)92K160K94K
Other Stockholders Equity00000
Minority Interest00000
Total Equity172.07M260.24M225.22M368.63M245.49M
Total Debt84.47M69.4M61.82M65.13M108.92M
Net Debt(128.37M)(33.88M)(40.04M)(112.75M)(214.61M)

Scholar Rock Holding Corporation

NASDAQ:SRRK

Intrinsic Alpha fair value

Locked

Current Price

$48.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.